个人中心 - 老虎社区

terry321

IP属地：未知

帖子 · 116帖子 · 116
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- terry321terry321
  ·2021-12-26
  Market will go up ot down this week? My guess.... down
  1,637 评论
  点赞
  分享
  举报
- terry321terry321
  ·2021-12-24
  Thanks for sharing
  How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
  Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for
  How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
  1,519 评论
  点赞
  分享
  举报
- terry321terry321
  ·2021-12-16
  I will buy Facebook instead of Telsa, AMD or Nvidia now
  非常抱歉，此主贴已删除
  1,188 3
  8
  分享
  举报
- terry321terry321
  ·2021-12-11
  Thanks for sharing
  非常抱歉，此主贴已删除
  1,076 评论
  1
  分享
  举报
- terry321terry321
  ·2021-11-27
  太可怕了
  非常抱歉，此主贴已删除
  1,265 1
  5
  分享
  举报
- terry321terry321
  ·2021-11-23
  Too late to buy now?
  Mizuho Bumps Up Western Digital Price Target By 36% On Improving Demand Trends From Amazon, Google
  Mizuho analyst Vijay Rakesh upgraded Western Digital Corp to Buy from Neutral with a price target of
  Mizuho Bumps Up Western Digital Price Target By 36% On Improving Demand Trends From Amazon, Google
  1,077 评论
  2
  分享
  举报
- terry321terry321
  ·2021-11-06
  $Pfizer(PFE)$终于等到了。continue....
  1,375 评论
  点赞
  分享
  举报
- terry321terry321
  ·2021-10-25
  $Zoom(ZM)$悄悄地升了
  1,119 评论
  点赞
  分享
  举报
- terry321terry321
  ·2021-10-25
  $Pfizer(PFE)$I believe I going to go up soon....
  832 评论
  点赞
  分享
  举报
- terry321terry321
  ·2021-10-19
  $Affirm Holdings, Inc.(AFRM)$太强了
  1,377 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3583058775200460","uuid":"3583058775200460","gmtCreate":1619965822263,"gmtModify":1624889538063,"name":"terry321","pinyin":"terry321","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":168,"tweetSize":116,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":698416318,"gmtCreate":1640490717428,"gmtModify":1640490717566,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"Market will go up ot down this week? My guess.... down","listText":"Market will go up ot down this week? My guess.... down","text":"Market will go up ot down this week? My guess.... down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698416318","isVote":1,"tweetType":1,"viewCount":1637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698348171,"gmtCreate":1640310432601,"gmtModify":1640310611457,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698348171","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-24 07:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690382394,"gmtCreate":1639635134095,"gmtModify":1639635341443,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"I will buy Facebook instead of Telsa, AMD or Nvidia now","listText":"I will buy Facebook instead of Telsa, AMD or Nvidia now","text":"I will buy Facebook instead of Telsa, AMD or Nvidia now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690382394","repostId":"1168308155","repostType":4,"isVote":1,"tweetType":1,"viewCount":1188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605281608,"gmtCreate":1639181187506,"gmtModify":1639181187606,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605281608","repostId":"1199826178","repostType":2,"isVote":1,"tweetType":1,"viewCount":1076,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600099341,"gmtCreate":1637997661000,"gmtModify":1637997661000,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"太可怕了","listText":"太可怕了","text":"太可怕了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600099341","repostId":"2186344334","repostType":4,"isVote":1,"tweetType":1,"viewCount":1265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875525732,"gmtCreate":1637672232438,"gmtModify":1637672232528,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"Too late to buy now?","listText":"Too late to buy now?","text":"Too late to buy now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875525732","repostId":"1199442564","repostType":4,"repost":{"id":"1199442564","kind":"news","pubTimestamp":1637670494,"share":"https://www.laohu8.com/m/news/1199442564?lang=&edition=full","pubTime":"2021-11-23 20:28","market":"us","language":"en","title":"Mizuho Bumps Up Western Digital Price Target By 36% On Improving Demand Trends From Amazon, Google","url":"https://stock-news.laohu8.com/highlight/detail?id=1199442564","media":"Benzinga","summary":"Mizuho analyst Vijay Rakesh upgraded Western Digital Corp to Buy from Neutral with a price target of","content":"<ul>\n <li><b>Mizuho</b>&nbsp;analyst Vijay Rakesh upgraded&nbsp;<b>Western Digital Corp</b>&nbsp;to Buy from Neutral&nbsp;with a price target of $75, up from $55, implying a 31.7% upside.</li>\n <li>Recent checks indicate demand is improving across the PC, server, and handset markets, Rakesh notes.</li>\n <li>The analyst believes server demand could improve in Q1 of 2022 with&nbsp;<b>Amazon.com Inc</b>&nbsp;and&nbsp;<b>Alphabet Inc</b>&nbsp;Google orders returning despite less than ten weeks of DRAM inventory.</li>\n <li>He sees improving demand trends and a \"tailwind\" for memory.</li>\n <li>Western Digital is a vertically-integrated supplier of data storage solutions, spanning both hard disk drives (HDDs) and solid-state drives (SSDs).</li>\n <li><b>Price Action:</b>WDC shares traded higher by 2.39% at $58.29 in the premarket session on the last check Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mizuho Bumps Up Western Digital Price Target By 36% On Improving Demand Trends From Amazon, Google</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMizuho Bumps Up Western Digital Price Target By 36% On Improving Demand Trends From Amazon, Google\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 20:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/11/24244443/mizuho-bumps-up-western-digital-price-target-by-36-on-improving-demand-trends-from-><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mizuho analyst Vijay Rakesh upgraded Western Digital Corp to Buy from Neutral with a price target of $75, up from $55, implying a 31.7% upside.\nRecent checks indicate demand is improving across the PC...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/11/24244443/mizuho-bumps-up-western-digital-price-target-by-36-on-improving-demand-trends-from-\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WDC":"西部数据"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/11/24244443/mizuho-bumps-up-western-digital-price-target-by-36-on-improving-demand-trends-from-","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199442564","content_text":"Mizuho analyst Vijay Rakesh upgraded Western Digital Corp to Buy from Neutral with a price target of $75, up from $55, implying a 31.7% upside.\nRecent checks indicate demand is improving across the PC, server, and handset markets, Rakesh notes.\nThe analyst believes server demand could improve in Q1 of 2022 with Amazon.com Inc and Alphabet Inc Google orders returning despite less than ten weeks of DRAM inventory.\nHe sees improving demand trends and a \"tailwind\" for memory.\nWestern Digital is a vertically-integrated supplier of data storage solutions, spanning both hard disk drives (HDDs) and solid-state drives (SSDs).\nPrice Action:WDC shares traded higher by 2.39% at $58.29 in the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1077,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842231038,"gmtCreate":1636178720874,"gmtModify":1636178721068,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>终于等到了。continue....","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>终于等到了。continue....","text":"$Pfizer(PFE)$终于等到了。continue....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842231038","isVote":1,"tweetType":1,"viewCount":1375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856995664,"gmtCreate":1635138216622,"gmtModify":1635138216775,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>悄悄地升了","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>悄悄地升了","text":"$Zoom(ZM)$悄悄地升了","images":[{"img":"https://static.tigerbbs.com/de8c62e9b0b53adc18806077e83b05ac","width":"1080","height":"2213"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856995664","isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":856995192,"gmtCreate":1635138178741,"gmtModify":1635138178893,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>I believe I going to go up soon....","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>I believe I going to go up soon....","text":"$Pfizer(PFE)$I believe I going to go up soon....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856995192","isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859091657,"gmtCreate":1634634910977,"gmtModify":1634634911145,"author":{"id":"3583058775200460","authorId":"3583058775200460","name":"terry321","avatar":"https://static.tigerbbs.com/f6b28703fdf50a2cae196db87a549ecc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583058775200460","authorIdStr":"3583058775200460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AFRM\">$Affirm Holdings, Inc.(AFRM)$</a>太强了","listText":"<a href=\"https://laohu8.com/S/AFRM\">$Affirm Holdings, Inc.(AFRM)$</a>太强了","text":"$Affirm Holdings, Inc.(AFRM)$太强了","images":[{"img":"https://static.tigerbbs.com/61acd9d661a92027f32b6cdff3f9739f","width":"1080","height":"2213"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859091657","isVote":1,"tweetType":1,"viewCount":1377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}